American Depositary Shares, each representing one ordinary share, nominal value 0.002 per share
- Symbol
- IMCR
- Exchange
- NASDAQ
- Classification
- ADS
- Status
- Current
Current Report · Items 2.02, 7.01, 8.01, 9.01 · 8-K
Immunocore Holdings plc
Results of Operations and Financial Condition · Regulation FD Disclosure · Other Events
Item 2.02. Results of Operations and Financial Condition. On January 9, 2026, Immunocore Holdings plc (the “Company”) announced a preliminary estimate of the amount of its cash, cash equivalents and marketable securities at December 31, 2025. The Company preliminarily estimates that its cash, cash equivalents and marketable securities as of December 31, 2025 were approximately $864 million.…
Press release in this filing
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference →Company context
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX - Immune mobilizing monoclonal TCRs Against X disease - designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Current securities
Recent company filings
Registered securities in this filing
Immunocore Holdings plc · 8-K · Filed 2026-01-09
Ordinary share, nominal value 0.002 per share*
- Symbol
- *
- Exchange
- NASDAQ
- Classification
- COMMON
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition.
On January 9, 2026, Immunocore Holdings plc (the “Company”) announced a preliminary estimate of the amount of its cash, cash
equivalents and marketable securities at December 31, 2025. The Company preliminarily estimates that its cash, cash equivalents and marketable securities as of December 31, 2025 were approximately $864 million.
The information in this Item 2.02 is preliminary, has not been audited and is subject to change pending completion of the Company’s
audited financial statements for the year ended December 31, 2025. It is possible that the Company or its independent registered public accounting firm may identify items that require the Company to make adjustments to the amounts included in this
Item 2.02, and such changes could be material. Additional information and disclosures would also be required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2025.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On January 9, 2026, the Company issued a press release announcing its strategic priorities for 2026. A copy of the press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Also on January 9, 2026, the Company updated its corporate presentation to reflect certain business and strategic updates. The
Company intends to use an abbreviated version of the presentation in meetings with analysts, investors and others from time to time, including its presentation by management at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
at 8:15 a.m. PT. A copy of the presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein. The corporate presentation and a webcast of the Company’s presentation at the 44th Annual J.P.
Morgan Healthcare Conference will also be available in the “Investors” section of the Company’s website at www.immunocore.com. The Company’s website and any information contained on the Company’s website are not incorporated by reference into this
Current Report on Form 8-K.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is
being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by
reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be
expressly set forth by specific reference in such filing.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On January 9, 2026, the Company published an updated pipeline chart of KIMMRAK (tebentafusp) and its therapeutic candidates in
development, which is filed as Exhibit 99.3 to this Current Report on Form 8-K and incorporated by reference herein.
Filed exhibits (2)
Exhibit 99.1 Immunocore announces 2026 strategic priorities at 44 Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US community and global market penetration Enrolling three Phase 3 trials across multiple melanoma indications - TEBE-AM enrollment completion anticipated 1H 2026; topline data expected as early as 2H 2026 PRAME franchise Phase 1/2 data to be presented in 2H 2026: brenetafusp combinations in ovarian and lung cancer and initial data with half-life extended candidate (IMC-P115C) Additional Phase 1 HIV data to be presented in 2H 2026 Planning to dose first patient in Phase 1 type 1 diabetes trial in 1H 2026 and to submit clinical trial application for second autoimmune candidate in 2H 2026 Company to present at 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 8:15 AM PST (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 9 January 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectio…
Open exhibit ↗Exhibit 99.2 Transformative immunomodulating medicines for patients January 2026 1 2 Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect”, “plan”, “anticipate”, “estimate”, “expect”, “continue” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. These statements include, but are not limited to, Immunocore’s capabilities across oncology, autoimmune and infectious disease therapeutic areas and its ability to advance its clinical and pre-clinical pipeline; the estimated market size and patient population for KIMMTRAK and Immunocore’s other product candidates; the growth opportunities for KIMMTRAK, including HLA-A02+ melanoma, cutaneous melanoma and adjuvant uveal melanoma; expected submission of investigational new drug applications or clinical trial applications; the potentia…
Open exhibit ↗